EditorialBPOG Special Section
White Paper: Container Closure Integrity Control versus Integrity Testing during Routine Manufacturing
Scott Ewan, Min Jiang, Chris Stevenson, Olivia Henderson, Steve Klohr, Martha Wessel, Pinky Mehta, Stefanie Adler, Cindy Lake, John Walsh, Tony Polomene and Valja Everaert
PDA Journal of Pharmaceutical Science and Technology May 2015, 69 (3) 461-465; DOI: https://doi.org/10.5731/pdajpst.2015.01071
Scott Ewan
Roles: (BPOG)
Min Jiang
Roles: (Abbvie)
Chris Stevenson
Roles: (Baxter)
Olivia Henderson
Roles: (Biogen)
Steve Klohr
Roles: (BMS)
Martha Wessel
Roles: (Eisai)
Pinky Mehta
Roles: (Janssen)
Stefanie Adler
Roles: (Janssen)
Cindy Lake
Roles: (Merck)
John Walsh
Roles: (Pfizer)
Tony Polomene
Roles: (Pfizer)
Valja Everaert
Roles: (Pfizer)

Reference
- 1.↵FDA Guidance for Industry: Container and Closure Integrity Testing in lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products, February 2008.
In This Issue
PDA Journal of Pharmaceutical Science and Technology
Vol. 69, Issue 3
May/June 2015
White Paper: Container Closure Integrity Control versus Integrity Testing during Routine Manufacturing
Scott Ewan, Min Jiang, Chris Stevenson, Olivia Henderson, Steve Klohr, Martha Wessel, Pinky Mehta, Stefanie Adler, Cindy Lake, John Walsh, Tony Polomene, Valja Everaert
PDA Journal of Pharmaceutical Science and Technology May 2015, 69 (3) 461-465; DOI: 10.5731/pdajpst.2015.01071
White Paper: Container Closure Integrity Control versus Integrity Testing during Routine Manufacturing
Scott Ewan, Min Jiang, Chris Stevenson, Olivia Henderson, Steve Klohr, Martha Wessel, Pinky Mehta, Stefanie Adler, Cindy Lake, John Walsh, Tony Polomene, Valja Everaert
PDA Journal of Pharmaceutical Science and Technology May 2015, 69 (3) 461-465; DOI: 10.5731/pdajpst.2015.01071
Jump to section
Related Articles
- No related articles found.